Among these cancers, non‐small cell lung cancer (NSCLC) accounts for approximately 40–50% of cases that include LM.1, 2 In recent years, the incidence of LM in patients with NSCLC has increased, especially in EGFR+ NSCLC patients, and 9.0% of EGFR+ NSCLC patients were diagnosed with LM.3, 4, 5 Whole brain radiotherapy (WBRT), systemic chemotherapy, and intrathecal chemotherapy (ITCT) are the traditional treatment choices for NSCLC patients with LM. Here, EGFR is linked to non-small cell lung carcinoma.